Licensed Oregon operator (Andreas Met) contributes integrated perspective spanning manufacturing, service centers, facilitation, and therapeutic psilocybin services

ASHLAND, OR / ACCESS Newswire / April 24, 2026 / Satya Inc.

Oregon Psilocybin Product Potency Workgroup Convenes to Review Dosing Standards

The Psilocybin Services section of the Oregon Health Authority convened a Psilocybin Product Potency Workgroup to examine how psilocybin product potency is measured, interpreted, and communicated within Oregon's regulated psilocybin services program.

The workgroup brought together representatives from across the licensed ecosystem, including:

• State regulators and policy staff

• Accredited laboratory representatives from the Oregon Environmental Laboratory Accreditation Program

• Licensed manufacturers

• Service center operators and licensed facilitators

The meeting was initiated in response to emerging concerns raised by laboratories and licensees regarding variability in psilocin content and its implications for dosing accuracy - particularly in lower-dose sessions and structured psilocybin-assisted therapeutic settings with shorter minimum durations. Discussion focused on whether current measurement standards, which primarily quantify psilocybin as the reference analyte, adequately reflect the full potency profile relevant to client experience, safety, and therapeutic outcomes within Oregon's regulated psilocybin services framework.

Satya Therapeutics Perspective: Aligning Regulation With Therapeutic Practice

Andreas Met, co-founder of Satya Therapeutics and a licensed psilocybin facilitator, participated in the workgroup representing the organization's integrated perspective across manufacturing, service center operations, and facilitation. Met brings a rare cross-role vantage point within Oregon's psilocybin services program, with direct, active experience across all three regulated roles, including therapeutic preparation, session facilitation, and integration support.

Drawing on experience supporting more than 250 clients through psilocybin-assisted therapeutic preparation, facilitation, and integration, Met emphasized the importance of aligning regulatory frameworks with real-world service delivery.

"Facilitators are already accounting for both psilocybin and psilocin when determining dose strength. The proposed Total Psilocybin Equivalent model reflects what experienced providers are doing every day to ensure safe, predictable outcomes in a therapeutic setting."

Met noted that variability in psilocin content is already present within the regulated supply chain and must be directly addressed in policy design to ensure consistency across psilocybin services.

"These are not theoretical edge cases. We're working with these products today, and it's important that regulatory frameworks reflect that reality so both safety and consistency are maintained."

He further emphasized that effective regulation depends not only on laboratory measurement standards, but also on how potency information is translated into practical decision-making within therapeutic psilocybin services.

"Clients need clarity, not complexity. What matters is helping people understand the effective strength of a dose in a way that is accurate and meaningful to their experience in a therapeutic context."

From a safety and facilitation standpoint, Met underscored that facilitator responsibility remains central regardless of measurement methodology.

"Facilitators have a clear obligation to ensure clients are ready before concluding a session. Strong practices, therapeutic presence, and informed decision-making are central to safety, regardless of how potency is measured."

He added that improving guidance materials could strengthen consistency across Oregon's regulated psilocybin services system.

"There's an opportunity to improve how potency information is communicated so it's more useful in practice. Simplifying that guidance would help both facilitators and clients make more informed decisions."

About Satya Therapeutics

Satya Therapeutics is an Oregon-licensed psilocybin service provider offering integrated manufacturing, facilitation, and service center operations. The organization provides psilocybin services within structured therapeutic preparation, facilitation, and integration frameworks supported by practitioner experience across the full licensed delivery system.

Contact:
www.satyatherapeutics.com
andreas@satyatherapeutics.com
(541) 930-2478

SOURCE: Satya Inc.